MAZE — Maze Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.87bn
- $1.49bn
- $167.50m
- 64
- 23
- 94
- 64
Annual cashflow statement for Maze Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -115 | -100 | 52.2 |
| Depreciation | |||
| Non-Cash Items | 15.2 | 15.8 | 21.9 |
| Unusual Items | |||
| Equity in Net Earnings/Losses | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -3.24 | -6.32 | -1.52 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -99.2 | -86.8 | 76 |
| Capital Expenditures | -1.97 | -0.441 | -1.15 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -1.2 | 0 | — |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -3.17 | -0.441 | -1.15 |
| Financing Cash Flow Items | — | — | -3.15 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 1.73 | 16.4 | 92.8 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -101 | -70.9 | 168 |